STAT+: We’re reading about an Ultragenyx failure, RevMed for lung cancer, and more

Today, we bring you a trio of updates from the world of medicine and research. First, we have troubling news from Ultragenyx regarding an experimental gene therapy for Angelman syndrome. The Phase 3 study showed no benefit compared to a placebo, despite early promising results. This failure is a significant setback for the company and its patients. Ultragenyx is now looking to cut costs as a result.

On a more positive note, a game-changing drug for advanced pancreatic cancer has once again shown promise. Just a week after receiving U.S. approval, the same therapy is now being tested against the world's biggest cancer killer - lung cancer. In a small trial of non-small cell lung cancer patients with specific RAS family protein mutations, the drug called Rasonque from RevMed shrank tumors in over 30% of participants. While a larger study is still underway, these early results are encouraging.

As we continue to follow these developments, stay tuned for more updates from the frontlines of medical progress.